The effect of inhaled nitric oxide in pediatric asthma

Area of Science:

• Pulmonary Medicine
• Pediatric Pulmonology
• Respiratory Physiology

Background:

• Nitric oxide (NO) regulates pulmonary vascular and airway smooth muscle tone.
• Previous studies in animals and adults suggest inhaled NO may have bronchodilatory potential.
• Limited data exist on NO's effects in pediatric asthma populations.

Purpose of the Study:

• To investigate the bronchodilatory effect of inhaled nitric oxide (NO) in children with asthma.
• To compare the effects of NO inhalation with albuterol on pediatric asthma lung function.

Main Methods:

• Spirometry was performed on 12 children with asthma (mean age 11.1 years).
• Pulmonary function tests were measured at baseline, after inhaling 40 ppm NO, and after albuterol.
• Measurements included forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and maximal expiratory flow rate (FEF-max).

Main Results:

• Inhaled NO at 40 ppm did not produce statistically significant changes in FVC, FEV1, FEF-max, or FEF25-75% compared to baseline.
• Inhaled albuterol significantly improved all measured pulmonary function parameters compared to baseline and NO inhalation.
• No significant differences were observed between baseline and NO inhalation at either time point (immediately after and 10 minutes).

Conclusions:

• Inhaled nitric oxide (NO) at 40 ppm demonstrates no significant bronchodilatory effect in pediatric asthma patients with mild airway disease.
• The therapeutic potential of inhaled NO as a bronchodilator in this population is questionable.
• Albuterol remains an effective bronchodilator for pediatric asthma.